A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

  • End date
    Apr 30, 2025
  • participants needed
  • sponsor
Updated on 2 April 2021


DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer


This study is modular in design allowing assessment of safety, tolerability and anti-tumour activity of T-DXd in combination with other anti-cancer agents. Combination-treatment modules will have 2 parts: a dose-finding phase (Part 1), and a dose expansion phase (Part 2); the recommended Phase 2 dose (RP2D) determined in Part 1 will be used for the dose-expansion in Part 2.

The target population of interest in this study is patients with HER2-positive (as per ASCO/CAP 2018 guidelines) advanced/MBC inclusive of patients with active and stable brain metastases. Part 1 of each module will enroll patients with locally assessed HER2-positive advanced/MBC in second-line or later patients. Part 2 of each module will enroll patients with locally assessed HER2-positive breast cancer who have not received prior treatment for advanced/metastatic disease.

Condition Metastatic Breast Cancer, Stage IV Breast Cancer
Treatment Paclitaxel, durvalumab, Pertuzumab, Tucatinib, Trastuzumab deruxtecan
Clinical Study IdentifierNCT04538742
Last Modified on2 April 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Stage IV Breast Cancer or Metastatic Breast Cancer?
Do you have any of these conditions: Metastatic Breast Cancer or Stage IV Breast Cancer?
Do you have any of these conditions: Stage IV Breast Cancer or Metastatic Breast Cancer?
Do you have any of these conditions: Stage IV Breast Cancer or Metastatic Breast Cancer?
Patients must be at least 18 years of age
Pathologically documented breast cancer that
Is advanced/unresectable (patients that can be treated with curative intent are not eligible) or metastatic
HER2-positive (IHC 3+ or IHC 2+/ISH+) based on local assessment
Is documented as hormone receptor-positive (estrogen or progesterone receptor) or negative in the metastatic setting
Patient must have adequate tumor sample for biomarker assessment
ECOG Performance Status of 0 or 1
Part 1
Disease progression on or after the last systemic therapy prior to starting study treatment
At least 1 prior treatment line in metastatic setting required
Part 2 (Modules 0 - 5)
No prior lines of therapy for advanced/MBC allowed
Part 2 (Module 6 and 7) a) Zero or one prior lines of therapy for advanced/MBC allowed
CNS Inclusion
Modules 0 - 5 Patients must have no brain metastases or stable brain metastases
Module 6 and 7 Patients must have untreated brain metastases not needing local therapy or previously treated brain metastases that have progressed since prior local therapy

Exclusion Criteria

Uncontrolled or significant cardiovascular disease
Active or prior documented (non-infectious) ILD/pneumonitis that required steroids, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
Lung-specific intercurrent clinically significant illnesses
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
Spinal cord compression or a history of leptomeningeal carcinomatosis
Prior treatment with immune checkpoint inhibitors
Prior treatment with an ADC containing a topoisomerase I inhibitor
Prior treatment with tucatinib
CNS Exclusion
Modules 0 - 5: Has untreated brain metastasis
Module 6 and 7: Ongoing use of systemic corticosteroids for control of symptoms of brain metastases or brain lesion thought to require immediate local therapy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note